New combo therapy targets tough liver tumors
NCT ID NCT05441475
Summary
This study is testing a new oral drug called ABSK-011, given alongside standard immunotherapy drugs, for people with advanced liver cancer that cannot be removed by surgery. The main goals are to see if the combination is safe and if it can help shrink tumors. The study will enroll about 118 adults who have not had prior systemic treatment or have only had one prior line of therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Hubei, Shanghai Municipality, 430030, China
Conditions
Explore the condition pages connected to this study.